- Psychiatric Annals
- July 2011 - Volume 41 · Issue 7: 347-349
In 2003, the FDA issued a warning for second-generation antipsychotics, including olanzapine and risperidone, among others, citing an increased risk for diabetes and hyperglycemia. The FDA stated that glucose levels should be monitored in patients with diabetes, at risk for diabetes or with symptoms of hyperglycemia. Concurrently, the American Diabetes Association and American Psychiatric Association recommended glucose and lipid testing for all patients started on second-generation antipsychotics.
(additional reporting by Angelo Milone)